食品和药物管理局已经批准了 " Journey Medical's Emrosi " 治疗罗萨切亚,1 600万美国人从中受益。 The FDA has approved Journey Medical's Emrosi to treat rosacea, benefiting 16 million Americans.
食品和药物管理局批准了 " Journey Medical's Emrosi " (一种低剂量的中子环球抗生素抗生素),用于治疗与Rosacea有关的发炎性损伤,这一慢性皮肤病影响到1 600多万美国人。 The FDA has approved Journey Medical's Emrosi, a low-dose minocycline antibiotic, for treating inflammatory lesions linked to rosacea, a chronic skin condition affecting over 16 million Americans. 批准之前成功进行了第三阶段临床试验,显示Emrosi与安慰剂和奥罗沙相比,在减少损伤和红度方面的效力。 The approval followed successful Phase 3 clinical trials showing Emrosi's efficacy in reducing lesions and redness compared to placebo and Oracea. Emrosi预计将在Q1晚期或Q22025年初提供,预计销售额至少为1.5亿美元。 Emrosi is expected to be available in late Q1 or early Q2 2025, with projected sales of at least $150 million.